The Synergic Effects of Agomelatine On The Anticancer Potential of Doxorubicin In Mcf-7 Breast Cancer Cells

Özkemahlı K. G. , Dincer B.

The 13th International Symposium on Pharmaceutical Sciences (ISOPS) , Ankara, Turkey, 22 - 25 June 2021, vol.1, no.1, pp.69

  • Publication Type: Conference Paper / Summary Text
  • Volume: 1
  • City: Ankara
  • Country: Turkey
  • Page Numbers: pp.69


Introduction: Treatment of breast cancer using doxorubicin (DOX), a potent antitumoral drug, is broadly considered one of the most common treatment modalities. However, the cytotoxic effects of the DOX significantly restrict its use, and also the development of resistance to DOX is frequently seen. Therefore, the combination therapies of DOX with different compounds and molecules to overcome drug resistance and minimize cytotoxic effect appears to be more promising in cancer cells (1). Melatonin (MEL) is a hormone secreted from the pineal gland and has an anti-proliferative effect on various tumor types (2). While many cancer studies on MEL are used as an adjuvant with chemotherapeutic drugs, no research in this direction has been found regarding agomelatine (AGO), which is MT1/MT2 melatonin receptor agonist. With the aim of developing a new adjuvant therapy, the present study tested the effects of AGO alone or combined with DOX on breast cancer. Materials and Methods: The effects of DOX, MEL, AGO, and their combinations (DOX+MEL and DOX+AGO) were investigated on the proliferation in the MCF-7 cells. The MCF-7 cells were separated into the following six groups: Control, DOX, MEL, AGO, DOX+MEL and DOX+AGO. Cell viability was determined by the 3- (4,5-dimethylthiazol- 2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay. The cells were exposed to appropriate nontoxic concentrations and incubation times for AGO by assessing cell viability in cell culture. Then cells were incubated with DOX, MEL, and AGO for 24 h.